PharmiWeb.com - Global Pharma News & Resources
15-Jul-2019

Epilepsy Market Worth Around 9,509.20 Million USD by 2023 | Lucrative CAGR 8.20% In International Market

Global epilepsy market is expected to reach USD 9,509.20 million by 2023 and the market is expected to register a CAGR of 8.20% during the forecast period from 2018 to 2023

The global epilepsy market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period till 2023. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period till 2023.

We can provide sample pages for a better understanding of this report.
Request Sample of This Report @ http://www.amecoresearch.com/sample/14710

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global epilepsy market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp;Africa).

Key Takeaways:

What is the market size in 2017 and the growth rate of the global epilepsy market?

What is the market drivers, restrains, opportunities governing the global epilepsy market?

Which are the largest and the fastest growing segments in the global epilepsy market?

Who are the key players operating in the market and their market position?

What is the pipeline scenario, drug pricing analysis and technological development in the market?

View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market/global-epilepsy-market-mrfr-14710

Epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the electrical functioning of the brain. Normally, the brain continuously develops tiny electrical impulse in an orderly pattern. The rising prevalence of epilepsy diseases and increasing healthcare expenditure drive the growth of the market. However, high per patient treatment cost and regulatory restriction on profitability may hamper the growth of the market.

The global epilepsy market is expected to register a CAGR of 8.20% during the forecast period of 2018 to 2023. In 2017, the market was led by the Americas with a 38.1% share. The market growth in this region is mainly due to the increasing prevalence of epilepsy disorders among the geriatric population. According to the statistics published by the Epilepsy Foundation of America Organization, 1.3 to 2.8 million people were diagnosed with epilepsy disease in the US in 2018.

The global epilepsy market has been segmented based on condition, diagnosis and treatment, end user, and region.

The condition segment is further segmented into drug-resistant epilepsy and others.

The global epilepsy market, by diagnosis and treatment, is segmented into diagnosis and treatment.

The global epilepsy market, by end user, is segmented into hospitals, clinics (family practitioners/ internal medicine), ambulatory surgical centers (outpatient centers), diagnostic centers, and others.
emsp;
Key Players

LivaNova PLC, GlaxoSmithKline PLC, Eisai Co. Ltd, Pfizer Inc., Medtronic PLC, UCB SA, NeuroPace Inc, GW Pharmaceuticals PLC, Novartis AG, Johnson amp; Johnson Services Inc., Abbott Laboratories, and others.

Study Objectives

To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the epilepsy market

To provide insights into factors affecting the market growth

To analyze the global epilepsy market based on various tools such as supply chain analysis and Porter's five force analysis

To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries

To provide country-level analysis of the market with respect to the current market size and future perspective

To provide country-level analysis of the market for segments by condition, diagnosis and treatment, end user, and region

To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the epilepsy market

Target Audience

Biotechnology Companies
Pharmaceutical Companies
Government Research Institutes
Academic Institutes and Universities
emsp;
Key Findings

The global epilepsy market is expected to reach USD 9,509.20 million by 2023 from USD 5,931.74 million in 2017 and is expected to register a CAGR of 8.20% during the forecast period from 2018 to 2023

On the basis of condition, the drug-resistant epilepsy segment accounted for the largest market share and is projected to register a CAGR of 9.07% from 2018 to 2023

Based on diagnosis and treatment, the treatment segment accounted for the largest market share and is anticipated to register a CAGR of 7.91% by the year 2023

Based on end user, the hospitals segment held the largest market share of 29.3% in 2017 and is projected to register a CAGR of 8.29% during the forecast period

The Americas is expected to hold the largest share of the global epilepsy market at a CAGR of 7.77% by 2023

Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 8.86% by 2023

Regional Analysis

Americas
North America
US
Canada
Latin America
Brazil
Rest of Latin America
Europe
Western Europe
Germany
France
UK
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
Middle East amp; Africa
Middle East
Saudi Arabia
Rest of the Middle East
Africa

Few Significant from Table Of Contents

Global Epilepsy Market Research Report Forecast to 2023

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions amp; Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising prevalence of epilepsy amongst the geriatric population
5.2.2 Increasing cases of brain injuries due to road accidents
5.2.3 Rising neurological disorders
5.2.4 Increasing research funding in epilepsy
5.3 Restraints
5.3.1 Loss of patent protection for branded drugs
5.3.2 High costs associated with the treatment of epilepsy
5.4 Opportunities
5.4.1 Entering developing economies
6 Market Factor Analysis
6.1 Porterrsquo;s Five Forces Analysis
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 Ramp;D
6.2.2 Manufacturing
6.2.3 Distribution
6.2.4 Marketing amp; Sales
6.2.5 Post-Sales Monitoring
6.3 Investment Opportunities
6.4 Pricing Analysis
6.5 Demographic Analysis
7 Global Epilepsy Market, by Condition
7.1 Overview
7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy
7.1.2 Others
8 Global Epilepsy Market, by Diagnosis amp; Treatment
8.1 Overview
8.1.1 Diagnosis amp; Treatment
9 Global Epilepsy Market, by End User
9.1 Overview
10 Global Epilepsy Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 Latin America
10.2.2.1 BRAZIL
10.2.2.2 REST OF LATIN AMERICA
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.2 Italy
10.3.3 Spain
10.3.4 Rest of Western Europe
10.3.5 Eastern Europe
10.4 Asia-Pacific
10.4.1.1 Japan
10.4.1.2 China
10.4.2 India
10.4.3 Australia
10.4.4 South Korea
10.4.5 Rest of Asia-Pacific
10.5 Middle East amp; Africa
10.6 Middle East
10.6.1.1 Saudi Arabia
10.6.1.2 Rest of Middle East
10.6.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.1.1 Introduction
12 Company Profile
12.1 LivaNova PLC
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 Key Development
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 GlaxoSmithKline PLC
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offered
12.2.4 Key Development
12.2.5 SWOT Analysis
12.2.6 Key Strategies
12.3 Eisai Co. Ltd
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offered
12.3.4 Key Development
12.3.5 SWOT Analysis
12.3.6 Key Strategies
12.4 Pfizer Inc
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategies
12.5 Medtronic PLC
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategies
12.6 UCB SA
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategies
12.7 NeuroPace Inc
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategies
12.8 GW Pharmaceuticals PLC
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategies
12.9 Novartis AG
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategies
12.1 Johnson amp; Johnson Services Inc.
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategies
12.11 Abbott Laboratories
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategies
13 Appendix
13.1 Discussion Blue Print

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/14710

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making a purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:

Email: sales@amecoresearch.com | +1 407 915 4157

Editor Details

Last Updated: 15-Jul-2019